Thermo Fisher expands into Switzerland as part of CSL collaboration
Just days after Thermo Fisher Scientific prepped to expand a St. Louis plant, the company announced it’s taking over a new, 1.5 million-square-foot site in Switzerland with plans to add 200 new employees.
The move is a part of a May 2020 partnership with CSL and the site, slated to be completed by next year, will first be used to manufacture CSL’s recombinant factor IX product Idelvion, a treatment for hemophilia B, with more treatments to be made there in the future.
Both single-use and stainless steel bioreactors will be used at the site, with up to 12,500-liter capacity, giving the companies the flexibility to manufacture from development all the way through large-scale production.
“We are excited to add the new Lengnau site to our global biologics manufacturing network and we are thrilled to welcome more than 200 new colleagues to Thermo Fisher,” Thermo EVP Michel Lagarde said in a statement. “Through our partnership with CSL, this site further strengthens our unique customer value proposition to leverage our scale and depth of capabilities for pharma and biotech customers. With the addition of new high-volume stainless-steel capabilities in Lengnau, we are enabling our customers to start their projects with us and stay with us as their manufacturing requirements grow.”
The Switzerland site is the latest announcement in an expanding group that includes sites in New Jersey, the Netherlands, Brisbane, Australia, Hangzhou, China and St. Louis.
The St. Louis site will see $82.5 million pumped into it, creating drug substance for treatments for cancer, Covid-19 and other life-threatening diseases. That comes after the company opened a new bioprocessing collaboration center in St. Louis in 2020, right next door to the site that’s set to get an upgrade.